"Following the gut The Anatara/Zoetis deal is a company maker"
Pitt Street Research Report
- Anatara is currently trading way below this valuation range
- Potential for Anatara to be re-rated by the market as GaRP progresses and as Zoetis gains regulatory approvals and launches Detach in North America, Europe and Asia.
- The opportunity for Detach is remarkable, given the size and scale of Zoetis' animal health portfolio
- Interest from one of the largest animal health companies worldwide reaffirms the credibility of the bromelain technology and reduces Anatara's cost burden, while providing a stream of cash flow to help the company move forward with its plans in human GI health
To view the research report, please visit:
About Anatara Lifesciences Ltd
Anatara Lifesciences (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing products for animal and human health. Following the successful licencing of our first product to leading global animal health company, Zoetis Inc, we are now focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders. For more information, please visit www.anataralifesciences.com.
Anatara Lifesciences Ltd